Aadi bioscience announces financial results for the fourth quarter and full-year 2022 and provides corporate update

Total revenue on fyarro® sales of $15.2 million for fy 2022 precision 1 trial preliminary data expected in the second quarter of 2023 conference call to be held today at 8:30 am edt los angeles , march 28, 2023 /prnewswire/ -- aadi bioscience, inc. (nasdaq: aadi), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mtor pathway genes, today provided a corporate update and announced financial results for the fourth quarter and full-year 2022. "2022 was a year marked by successive milestones with the launch of fyarro, the start of the precision 1 trial, strengthening our balance sheet with a $72.5 million financing, taking our cash runway into 2025, and collaborating on a new combination of nab-sirolimus with mirati's adagrasib," said scott giacobello, cfo and interim president and ceo of aadi bioscience.
AADI Ratings Summary
AADI Quant Ranking